Trained on millions of data points, Whiterabbit’s ACT is designed to facilitate compliance among women with mammography recommendations using a personalized notification system that does not require intensive one-on-one follow ups. Additionally, ACT evenly distributes a clinic’s increase in patient volume throughout the year. Tested in more than 300 breast cancer screening centers across the U.S., ACT has a proven track record of more than 20 percent growth year over year in breast cancer screening volume.
About Whiterabbit
Whiterabbit.ai is an AI technology company with a mission to improve lives through earlier, more accurate cancer detection. A growing number of radiologists and healthcare providers are using Whiterabbit's technology to improve patients' experience with breast cancer screening. In addition to ACT, Whiterabbit has developed two other product lines – WRDensity and WRRisk. WRDensity is an FDA-cleared artificial intelligence-driven software that helps radiologists better assess breast density. WRRisk, a clinical decision support software for risk assessment based on well-established breast cancer risk models, assigns a risk rating to a patient and provides vital information to a physician to create a more personalized screening regimen with consistent follow-up and more accurate clinical diagnosis. Whiterabbit is headquartered in Santa Clara, California.
About Arterys
Arterys is the market leader and the world's first internet platform for medical imaging. It offers the most comprehensive set of clinical AI workflow solutions in one platform that delivers the highest return on investment, combined with the lowest cost to implement and manage. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.
Back to HCB News
